dopamine + norepinephrine

This entry refers to the comparative use of dopamine and norepinephrine as first-line vasopressor therapies in the management of various types of shock, including septic, cardiogenic, and hypovolemic shock. Dopamine is a catecholamine precursor that acts on dopaminergic, beta-1 adrenergic, and alpha-adrenergic receptors in a dose-dependent manner to increase cardiac output and systemic vascular resistance. Norepinephrine is a potent catecholamine that primarily targets alpha-1 adrenergic receptors to induce systemic vasoconstriction, with moderate beta-1 adrenergic activity that increases heart rate and contractility. The landmark SOAP II (Sepsis Occurrence in Acutely Ill Patients II) trial compared these two agents and established norepinephrine as the preferred first-line vasopressor due to a significantly lower incidence of arrhythmic events compared to dopamine, particularly in patients with cardiogenic shock.

Brand names

IntropinLevophed

Other names

SOAP II trial drugsdopamine versus norepinephrine